SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza

SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza

June 29, 2021
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp.

SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp.

June 22, 2021
SAB Biotherapeutics to Participate in Expert Panel at BIO Digital 2021

SAB Biotherapeutics to Participate in Expert Panel at BIO Digital 2021

June 14, 2021
SAB Biotherapeutics Appoints Carlos Carrillo, PhD, as Senior Vice President, Regulatory Affairs

SAB Biotherapeutics Appoints Carlos Carrillo, PhD, as Senior Vice President, Regulatory Affairs

June 10, 2021

SAB Biotherapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference

May 14, 2021
SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial

SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial

April 21, 2021

SAB Biotherapeutics to Present at Upcoming March Investor Conferences

March 4, 2021

SAB Biotherapeutics Announces New Appointments to its Board of Directors

December 15, 2020

SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19

November 30, 2020

SAB Biotherapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of SAB-185 For The Treatment Of COVID-19

August 21, 2020

SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-185 For The Treatment And Prevention Of COVID-19

August 11, 2020

SAB Biotherapeutics Awarded $35.6M From U.S. Department Of Defense For COVID-19 And Scaling Rapid Response Antibody Program

August 6, 2020